SLU-PP-332: The "Exercise Mimetic" Compound Explained
SLU-PP-332 is a synthetic ERR agonist that switches on the metabolic gene program of endurance exercise, at least in mice. It is marketed as an exercise mimetic and sold alongside research peptides, though it is not a peptide and has no verified human clinical evidence in the sources reviewed here. Here is what the science shows and what it does not.
What Is SLU-PP-332?
SLU-PP-332 is a small synthetic molecule developed by researchers at Saint Louis University as an agonist of the estrogen-related receptors. It drew attention because mice given the compound showed the metabolic hallmarks of endurance training, more energy burned and more fat oxidized, without running any further than usual.
That result, an exercise-like effect under animal-study administration, is why the compound spread through fitness and longevity circles. It is now sold by the same vendors that handle research peptides, which is how it picked up the peptide label it does not deserve.
Why It Is Not Actually a Peptide
A peptide is a short chain of amino acids linked by peptide bonds. SLU-PP-332 has neither. It is a small-molecule drug candidate, structurally closer to a conventional pharmaceutical than to BPC-157 or a GLP-1 agonist.
The peptide label is marketing, not chemistry. It sits beside compounds like MK-677, RAD-140, and turkesterone, non-peptide research chemicals that share a marketplace and an audience but not a molecular class. Keeping that distinction straight matters because the safety questions differ by class.
How It Works: The ERR Pathway
The estrogen-related receptors (ERR alpha, beta, and gamma) are nuclear receptors that regulate genes controlling mitochondrial biogenesis, fatty acid oxidation, and cellular respiration. Endurance exercise activates this same network, which is how training builds aerobic capacity over time.
SLU-PP-332 activates these receptors directly. In doing so it turns on the downstream genes pharmacologically rather than through physical work. The result in animals is a metabolic state that looks, at the level of gene expression and energy use, like the aftermath of exercise. For background on receptor-driven signaling, see peptide hormones.
What the Research Shows
In rodent studies, SLU-PP-332 raised whole-body energy expenditure, increased fatty acid oxidation, improved running endurance, reduced fat mass accumulation, and improved insulin sensitivity in models of metabolic syndrome. Later medicinal-chemistry work dissected the molecule to identify which structural features drive ERR activity, groundwork for optimizing the scaffold.
Read that list with the qualifier attached: every finding is preclinical, in mice and in cell-based assays. Impressive animal metabolic results are common and frequently fail to translate to humans. The compound is a legitimate research lead, not a validated therapy.
The Human Evidence Gap
The selected original research reviewed here does not establish human efficacy, pharmacokinetics, safety or a dose. The selected original studies are preclinical; their results cannot establish absence of human exposure everywhere. Any dosing protocol you find online is extrapolated from milligram-per-kilogram mouse studies, a conversion that is unreliable and ignores species differences in receptor distribution and metabolism.
This is the same evidence problem that runs through much of the research compound market: promising mechanism, no human validation, sold anyway. The pattern is worth recognizing because it recurs with almost every new compound that trends.
Safety and Unknowns
The assessed preclinical studies do not establish a human safety profile. The ERR receptors it targets are expressed across many tissues, including the heart, so broad pharmacological activation could produce effects far from the intended fat-metabolism benefit. The sources reviewed here do not characterize those risks in people.
On top of the biological uncertainty sits a supply problem. A research label, supplier claim or nominal purity percentage alone cannot establish identity, active amount, sterility or human-use suitability. The sources here do not establish that every seller performs no testing. The combined risk, unknown biology plus unknown product quality, is covered in gray-market risks and peptide testing and quality.
Legal and Regulatory Status
The assessed research does not supply an approved clinical product or substantiate a dietary-supplement claim. It is sold as a research chemical, typically labeled not for human consumption, which does not create a legal safe harbor or permission for human use. Purchasing it for personal use places you in the same unregulated channel discussed in are peptides legal.
Advisory consideration of specific nominated peptide forms does not establish approval, reclassification or permission for this different small molecule. See the FDA peptide category update for what that change does and does not cover.
Can It Replace Exercise?
No, and the framing oversells it. SLU-PP-332 reproduces one slice of exercise biology, the metabolic gene signature, in animals. Real exercise also strengthens the heart, builds muscle and bone, sharpens cognition, and lifts mood through pathways a single receptor agonist does not engage.
The most it could plausibly become, if human trials ever confirm the animal work, is a metabolic adjunct for people who cannot exercise, not a shortcut around training. The reviewed evidence remains preclinical and does not establish a human exercise substitute. For the broader category, see growth hormone peptides and peptides for fat loss.
Related Guides
Research Peptides
How the gray market for research compounds works and where the risks sit.
MK-677
Another non-peptide research compound sold in the same market.
Peptides for Fat Loss
The wider landscape of compounds marketed for metabolism and fat loss.
Gray-Market Risks
What you are actually buying when a product says research only.
Turkesterone
A popular performance supplement with a similar evidence problem.
What Are Peptides?
The chemistry that separates real peptides from small molecules.
Original 2023 exercise-capacity research and metabolic-syndrome mouse research support the positive preclinical findings above. The 2026 development report states that SLU-PP-332 lacks oral bioavailability and distinguishes orally active SLU-PP-915, another molecule. An online capsule is not validated by a mouse injection or another analogue. These indexed original abstracts were read; not all full papers were obtained.
Check registered research: SLU-PP-332 intervention search. No generic home-dose or route conversion follows from the preclinical sources assessed here.
Frequently Asked Questions About SLU-PP-332
SLU-PP-332 is a synthetic small-molecule ERR agonist, not a peptide. Original mouse/cell studies show selected exercise-like metabolic and endurance effects.
No. It is a small molecule rather than an amino-acid chain; shared research-market branding does not change chemistry.
It activates ERR-associated gene programs in experimental systems. Animal metabolic effects do not establish a human clinical response.
Original mouse work found favorable endurance, energy-expenditure, fat-oxidation and metabolic-syndrome measures. These positive findings remain preclinical, not a validated human exercise replacement.
The selected original studies reviewed here are preclinical and do not establish human efficacy, PK or safety. They cannot prove that no human exposure occurred anywhere.
Human safety is not established by the assessed mouse/cell evidence. Systemic receptor activity raises questions rather than proving a particular human adverse-event rate; product quality also needs its own evidence.
The reviewed sources do not supply an approved clinical product or complete current jurisdiction-specific legal assessment. A research-use disclaimer is not approval or a safe harbor.
The assessed work reproduces selected exercise-related findings in mice. It does not establish replacement of the many health effects of exercise in people or a safe human protocol.